{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T20:16:44Z","timestamp":1785010604113,"version":"3.55.0"},"reference-count":100,"publisher":"MDPI AG","issue":"1","license":[{"start":{"date-parts":[[2015,1,5]],"date-time":"2015-01-05T00:00:00Z","timestamp":1420416000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Agomelatine, a melatonergic antidepressant with a rapid onset of action, is one of the most recent drugs in the antidepressant category. Agomelatine\u2019s antidepressant actions are attributed to its sleep-promoting and chronobiotic actions mediated by MT1 and MT2 receptors present in the suprachiasmatic nucleus, as well as to its effects on the blockade of 5-HT2c receptors. Blockade of 5-HT2c receptors causes release of both noradrenaline and dopamine at the fronto-cortical dopaminergic and noradrenergic pathways. The combined actions of agomelatine on MT1\/MT2 and 5-HT2c receptors facilitate the resynchronization of altered circadian rhythms and abnormal sleep patterns. Agomelatine appeared to be effective in treating major depression. Moreover, evidence exists that points out a possible efficacy of such drug in the treatment of bipolar depression, anxiety disorders, alcohol dependence, migraines etc. Thus, the aim of this narrative review was to elucidate current evidences on the role of agomelatine in disorders other than major depression.<\/jats:p>","DOI":"10.3390\/ijms16011111","type":"journal-article","created":{"date-parts":[[2015,1,5]],"date-time":"2015-01-05T10:17:08Z","timestamp":1420453028000},"page":"1111-1130","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":68,"title":["Agomelatine beyond Borders: Current Evidences of Its Efficacy in Disorders Other than Major Depression"],"prefix":"10.3390","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4415-5058","authenticated-orcid":false,"given":"Domenico","family":"De Berardis","sequence":"first","affiliation":[{"name":"National Health Service, Department of Mental Health, Psychiatric Service of Diagnosis and Treatment, Hospital \"G. Mazzini\", ASL 4, 64100 Teramo, Italy"},{"name":"Department of Neuroscience and Imaging, University \"G. D'Annunzio\", 66013 Chieti, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Fornaro","sequence":"additional","affiliation":[{"name":"Department of \"Scienze della Formazione\", University of Catania, 95121 Catania, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"Serroni","sequence":"additional","affiliation":[{"name":"Department of Neuroscience and Imaging, University \"G. D'Annunzio\", 66013 Chieti, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Campanella","sequence":"additional","affiliation":[{"name":"Department of Neuroscience and Imaging, University \"G. D'Annunzio\", 66013 Chieti, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriella","family":"Rapini","sequence":"additional","affiliation":[{"name":"Department of Neuroscience and Imaging, University \"G. D'Annunzio\", 66013 Chieti, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luigi","family":"Olivieri","sequence":"additional","affiliation":[{"name":"National Health Service, Department of Mental Health, Psychiatric Service of Diagnosis and Treatment, Hospital \"G. Mazzini\", ASL 4, 64100 Teramo, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Venkataramanujam","family":"Srinivasan","sequence":"additional","affiliation":[{"name":"Sri Sathya Sai Medical Educational and Research Foundation, Medical Sciences Research Study Center, Prasanthi Nilayam, 40-Kovai Thirunagar Coimbatore-641014, 641014 Tamilnadu, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felice","family":"Iasevoli","sequence":"additional","affiliation":[{"name":"Laboratory of Molecular Psychiatry and Psychopharmacotherapeutics, Section of Psychiatry, Department of Neuroscience, University School of Medicine \"Federico II\", 80131 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmine","family":"Tomasetti","sequence":"additional","affiliation":[{"name":"Laboratory of Molecular Psychiatry and Psychopharmacotherapeutics, Section of Psychiatry, Department of Neuroscience, University School of Medicine \"Federico II\", 80131 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"De Bartolomeis","sequence":"additional","affiliation":[{"name":"Laboratory of Molecular Psychiatry and Psychopharmacotherapeutics, Section of Psychiatry, Department of Neuroscience, University School of Medicine \"Federico II\", 80131 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Valchera","sequence":"additional","affiliation":[{"name":"Hermanas Hospitalarias, FoRiPsi, Villa S. Giuseppe Hospital, 63100 Ascoli Piceno, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giampaolo","family":"Perna","sequence":"additional","affiliation":[{"name":"Hermanas Hospitalarias, FoRiPsi, Department of Clinical Neurosciences,  Villa San Benedetto Menni, Albese con Cassano, 22032 Como, Italy"},{"name":"Department of Psychiatry and Behavioral Sciences, Leonard Miller School of Medicine,  University of Miami, Miami, FL 33124, USA"},{"name":"Department of Psychiatry and Neuropsychology, University of Maastricht, 6200 MD Maastricht,  The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica","family":"Mazza","sequence":"additional","affiliation":[{"name":"Department of Life, Health and Environmental Sciences, University of L'Aquila,  67100 L'Aquila, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Di Nicola","sequence":"additional","affiliation":[{"name":"Institute of Psychiatry and Psychology, Catholic University of Sacred Heart, 00168 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Martinotti","sequence":"additional","affiliation":[{"name":"Department of Neuroscience and Imaging, University \"G. D'Annunzio\", 66013 Chieti, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimo","family":"Di Giannantonio","sequence":"additional","affiliation":[{"name":"Department of Neuroscience and Imaging, University \"G. D'Annunzio\", 66013 Chieti, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2015,1,5]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1517\/13543784.2012.711314","article-title":"Role of melatonin in mood disorders and the antidepressant effects of agomelatine","volume":"21","author":"Srinivasan","year":"2012","journal-title":"Expert Opin. Investig. Drugs"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"12458","DOI":"10.3390\/ijms140612458","article-title":"The melatonergic system in mood and anxiety disorders and the role of agomelatine: Implications for clinical practice","volume":"14","author":"Marini","year":"2013","journal-title":"Int. J. Mol. Sci."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1016\/j.pnpbp.2005.04.032","article-title":"Antidepressant action of agomelatine (S 20098) in a transgenic mouse model","volume":"29","author":"Barden","year":"2005","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1517\/14656566.2014.862233","article-title":"The mechanism, efficacy, and tolerability profile of agomelatine","volume":"15","author":"MacIsaac","year":"2014","journal-title":"Expert Opin. Pharmacother."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1034\/j.1600-079X.2001.280309.x","article-title":"Circadian rhythm of mt1 melatonin receptor expression in the suprachiasmatic nucleus of the C3H\/HeN mouse","volume":"28","author":"Masana","year":"2000","journal-title":"J. Pineal Res."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.pneurobio.2007.05.002","article-title":"Electrophysiology of the suprachiasmatic circadian clock","volume":"82","author":"Brown","year":"2007","journal-title":"Prog. Neurobiol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1111\/j.1365-2265.2005.02341.x","article-title":"Phase-shifts of 24 h rhythms of hormonal release and body temperature following early evening administration of the melatonin agonist agomelatine in healthy older men","volume":"63","author":"Leproult","year":"2005","journal-title":"Clin. Endocrinol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1016\/j.euroneuro.2012.06.016","article-title":"Synergistic mechanisms involved in the antidepressant effects of agomelatine","volume":"22","author":"Tardito","year":"2012","journal-title":"Eur. Neuropsychopharmacol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/j.pbb.2011.02.015","article-title":"Memory facilitating effects of agomelatine in the novel object recognition memory paradigm in the rat","volume":"98","author":"Seguin","year":"2011","journal-title":"Pharmacol. Biochem. Behav."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1016\/j.eurpsy.2008.04.002","article-title":"Agomelatine: A novel mechanism of antidepressant action involving the melatonergic and the serotonergic system","volume":"23","author":"San","year":"2008","journal-title":"Eur. Psychiatry"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"287","DOI":"10.2174\/157015910792246227","article-title":"A systematic, updated review on the antidepressant agomelatine focusing on its melatonergic modulation","volume":"8","author":"Fornaro","year":"2010","journal-title":"Curr. Neuropharmacol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"907","DOI":"10.2147\/NDT.S63459","article-title":"Electroretinographic modifications induced by agomelatine: A novel avenue to the understanding of the claimed antidepressant effect of the drug?","volume":"10","author":"Fornaro","year":"2014","journal-title":"Neuropsychiatr. Dis. Treat."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"119","DOI":"10.2174\/187152711794488674","article-title":"The emerging role of melatonin agonists in the treatment of major depression: Focus on agomelatine","volume":"10","author":"Acciavatti","year":"2011","journal-title":"CNS Neurol. Disord. Drug Targets"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/j.euroneuro.2012.07.004","article-title":"Anhedonia and major depression: The role of agomelatine","volume":"22","author":"Martinotti","year":"2012","journal-title":"Eur. Neuropsychopharmacol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"412","DOI":"10.3109\/15622975.2013.765593","article-title":"Agomelatine, a novel intriguing antidepressant option enhancing neuroplasticity: A critical review","volume":"14","author":"Pompili","year":"2013","journal-title":"World J. Biol. Psychiatry"},{"key":"ref_16","first-page":"109","article-title":"Major depressive disorder, anhedonia and agomelatine: An open-label study","volume":"25","author":"Guglielmo","year":"2011","journal-title":"J. Biol. Regul. Homeost. Agents"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1097\/WNF.0000000000000009","article-title":"Successful use of agomelatine in the treatment of major depression in a woman taking tamoxifen: A case report","volume":"37","author":"Brucchi","year":"2014","journal-title":"Clin. Neuropharmacol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1016\/j.jad.2012.10.004","article-title":"Reduced hedonic capacity in euthymic bipolar subjects: A trait-like feature?","volume":"147","author":"Battaglia","year":"2013","journal-title":"J. Affect. Disord."},{"key":"ref_19","first-page":"10","article-title":"Anhedonia and substance dependence: Clinical correlates and treatment options","volume":"17","author":"Hatzigiakoumis","year":"2011","journal-title":"Front. Psychiatry"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1176\/appi.neuropsych.12110286","article-title":"Agomelatine treatment of major depressive disorder in Parkinson\u2019s disease: A case series","volume":"25","author":"Fornaro","year":"2013","journal-title":"J. Neuropsychiatry Clin. Neurosci."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1007\/s00213-011-2597-5","article-title":"Agomelatine (S20098) modulates the expression of cytoskeletal microtubular proteins, synaptic markers and BDNF in the rat hippocampus, amygdala and PFC","volume":"221","author":"Ladurelle","year":"2012","journal-title":"Psychopharmacology"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1097\/JCP.0b013e31825d6c25","article-title":"Agomelatine vs venlafaxine XR in the treatment of anhedonia in major depressive disorder: A pilot study","volume":"32","author":"Martinotti","year":"2012","journal-title":"J. Clin. Psychopharmacol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1016\/j.euroneuro.2014.01.006","article-title":"A placebo-controlled study of three agomelatine dose regimens (10 mg, 25 mg, 25\u201350 mg) in patients with major depressive disorder","volume":"24","author":"Kennedy","year":"2014","journal-title":"Eur. Neuropsychopharmacol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1097\/YIC.0b013e32833a86aa","article-title":"Superior antidepressant efficacy results of agomelatine vs. fluoxetine in severe MDD patients: A randomized, double-blind study","volume":"25","author":"Hale","year":"2010","journal-title":"Int. Clin. Psychopharmacol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"109","DOI":"10.4088\/JCP.09m05347blu","article-title":"Efficacy of the novel antidepressant agomelatine on the circadian rest-activity cycle and depressive and anxiety symptoms in patients with major depressive disorder: A randomized, double-blind comparison with sertraline","volume":"71","author":"Kasper","year":"2010","journal-title":"J. Clin. Psychiatr."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1017\/S1461145713000679","article-title":"Efficacy of agomelatine and escitalopram on depression, subjective sleep and emotional experiences in patients with major depressive disorder: A 24-wk randomized, controlled, double-blind trial","volume":"16","author":"Corruble","year":"2013","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1177\/0004867414525837","article-title":"Comparison of agomelatine and selective serotonin reuptake inhibitors\/serotonin-norepinephrine reuptake inhibitors in major depressive disorder: A meta-analysis of head-to-head randomized clinical trials","volume":"48","author":"Huang","year":"2014","journal-title":"Aust. N. Z. J. Psychiatry"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"587","DOI":"10.4088\/JCP.12m08250","article-title":"The efficacy of agomelatine in elderly patients with recurrent major depressive disorder: A placebo-controlled study","volume":"74","author":"Heun","year":"2013","journal-title":"J. Clin. Psychiatry"},{"key":"ref_29","unstructured":"European Medicines Agency (2008). CHMP Assessment Report for Valdoxan. Document Reference EMEA\/655251\/2008, European Medicines Agency."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"g1888","DOI":"10.1136\/bmj.g1888","article-title":"Antidepressant efficacy of agomelatine: Meta-analysis of published and unpublished studies","volume":"348","author":"Taylor","year":"2014","journal-title":"BMJ"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1192\/bjp.bp.112.120196","article-title":"Agomelatine efficacy and acceptability revisited: Systematic review and meta-analysis of published and unpublished randomised trials","volume":"203","author":"Koesters","year":"2013","journal-title":"Br. J. Psychiatry"},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Guaiana, G., Gupta, S., Chiodo, D., Davies, S.J., Haederle, K., and Koesters, M. (2013). Agomelatine vs. other antidepressive agents for major depression. Cochrane Database Syst. Rev., 12, CD008851.","DOI":"10.1002\/14651858.CD008851.pub2"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1177\/0269881108096507","article-title":"Better sexual acceptability of agomelatine (25 and 50 mg) compared with paroxetine (20 mg) in healthy male volunteers: An 8-week, placebo-controlled study using the PRSEXDQ-SALSEX scale","volume":"24","author":"Montejo","year":"2010","journal-title":"J. Psychopharmacol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1097\/01.yic.0000137184.64610.c8","article-title":"Absence of discontinuation symptoms with agomelatine and occurrence of discontinuation symptoms with paroxetine: A randomized, double-blind, placebo-controlled discontinuation study","volume":"19","author":"Montgomery","year":"2004","journal-title":"Int. Clin. Psychopharmacol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"709","DOI":"10.2165\/11593960-000000000-00000","article-title":"A benefit-risk assessment of agomelatine in the treatment of major depression","volume":"34","author":"Howland","year":"2011","journal-title":"Drug Saf."},{"key":"ref_36","unstructured":"Servier Laboratories Ltd. Available online:http:\/\/emc.medicines.org.uk\/medicine\/21830\/SPC\/Valdoxan\/."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1517\/17425255.2014.907794","article-title":"Pharmacokinetic evaluation of agomelatine for the treatment of generalised anxiety disorder","volume":"10","author":"Buoli","year":"2014","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"401","DOI":"10.31887\/DCNS.2012.14.4\/fbenedetti","article-title":"Antidepressant chronotherapeutics for bipolar depression","volume":"14","author":"Benedetti","year":"2012","journal-title":"Dialogues Clin. Neurosci."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1016\/j.jad.2013.07.004","article-title":"Treatment adherence towards prescribed medications in bipolar-II acute depressed patients: Relationship with cyclothymic temperament and \u201ctherapeutic sensation seeking\u201d in response towards subjective intolerance to pain","volume":"151","author":"Fornaro","year":"2013","journal-title":"J. Affect. Disord."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1111\/j.1399-5618.2007.00507.x","article-title":"Agomelatine adjunctive therapy for acute bipolar depression: Preliminary open data","volume":"9","author":"Calabrese","year":"2007","journal-title":"Bipolar Disord."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"243","DOI":"10.2147\/NDT.S41557","article-title":"Adjunctive agomelatine therapy in the treatment of acute bipolar II depression: A preliminary open label study","volume":"9","author":"Fornaro","year":"2013","journal-title":"Neuropsychiatr. Dis. Treat."},{"key":"ref_42","first-page":"1037","article-title":"Seasonal affective disorder","volume":"86","author":"Kurlansik","year":"2012","journal-title":"Am. Fam. Phys."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"315","DOI":"10.31887\/DCNS.2007.9.3\/rlevitan","article-title":"The chronobiology and neurobiology of winter seasonal affective disorder","volume":"9","author":"Levitan","year":"2007","journal-title":"Dialogues Clin. Neurosci."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1177\/074873048800300203","article-title":"Winter depression and the phase-shift hypothesis for bright light\u02bcs therapeutic effects: History, theory, and experimental evidence","volume":"3","author":"Lewy","year":"1988","journal-title":"J. Biol. Rhythym."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1007\/s00213-006-0645-3","article-title":"Agomelatine in the treatment of seasonal affective disorder","volume":"190","author":"Pjrek","year":"2007","journal-title":"Psychopharmacology"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"2813","DOI":"10.1111\/j.1742-4658.2006.05322.x","article-title":"Melatonin: nature\u2019s most versatile biological signal?","volume":"273","author":"Srinivasan","year":"2006","journal-title":"FEBS J."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"S230","DOI":"10.1016\/S0924-977X(04)80215-3","article-title":"Evidence for antidepressant and anxiolytic-like activities of melatonin and agomelatine in animal models","volume":"14","author":"Gruca","year":"2004","journal-title":"Eur. Neuropsychopharmacol."},{"key":"ref_48","first-page":"59","article-title":"The melatonergic system: Effects on sleep and implications for the treatment of psychiatric disorders","volume":"1","author":"Acciavatti","year":"2011","journal-title":"ChronoPhysiol. Ther."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1007\/s00213-004-1962-z","article-title":"Anxiolytic properties of agomelatine, an antidepressant with melatoninergic and serotonergic properties: Role of 5-HT2C receptor blockade","volume":"177","author":"Millan","year":"2005","journal-title":"Psychopharmacology"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1124\/jpet.103.051797","article-title":"The novel melatonin agonist agomelatine (S20098) is an antagonist at 5-hydroxytryptamine2C receptors, blockade of which enhances the activity of frontocortical dopaminergic and adrenergic pathways","volume":"306","author":"Millan","year":"2003","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1016\/S0959-4388(98)80094-9","article-title":"Molecular rhythms in the pineal gland","volume":"8","author":"Li","year":"1998","journal-title":"Curr. Opin. Neurobiol."},{"key":"ref_52","first-page":"473","article-title":"The comparative dose-response effects of melatonin and midazolam for premedication of adult patients: A double-blinded, placebo-controlled study","volume":"91","author":"Naguib","year":"2000","journal-title":"Anesth. Analg."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.bbr.2011.03.029","article-title":"The effects of the intraamygdalar melatonin injections on the anxiety like behavior and the spatial memory performance in male Wistar rats","volume":"222","author":"Kaya","year":"2011","journal-title":"Behav. Brain Res."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1254\/jphs.11183FP","article-title":"Melatonin modulates the GABAergic response in cultured rat hippocampal neurons","volume":"119","author":"Cheng","year":"2012","journal-title":"J. Pharmacol. Sci."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1002\/hup.2294","article-title":"Efficacy of the novel antidepressant agomelatine for anxiety symptoms in major depression","volume":"28","author":"Stein","year":"2013","journal-title":"Hum. Psychopharmacol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1097\/JCP.0b013e318184ff5b","article-title":"Efficacy of agomelatine in generalized anxiety disorder: A randomized, double-blind, placebo-controlled study","volume":"28","author":"Stein","year":"2008","journal-title":"J. Clin. Psychopharmacol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.pnpbp.2010.09.020","article-title":"Agomelatine in the treatment of panic disorder","volume":"35","author":"Fornaro","year":"2011","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/1744-859X-10-5","article-title":"Switching from serotonin reuptake inhibitors to agomelatine in patients with refractory obsessive-compulsive disorder: A 3 month follow-up case series","volume":"10","author":"Fornaro","year":"2011","journal-title":"Ann. Gen. Psychiatry"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1097\/JCP.0b013e318249298c","article-title":"A case of obsessive-compulsive disorder successfully treated with agomelatine monotherapy","volume":"32","author":"Serroni","year":"2012","journal-title":"J. Clin. Psychopharmacol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1177\/039463201302600203","article-title":"Is there a role for agomelatine in the treatment of anxiety disorders? A review of published data","volume":"26","author":"Conti","year":"2013","journal-title":"Int. J. Immunopathol. Pharmacol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1097\/WNF.0b013e318223421f","article-title":"Is circadian rhythm disruption important in obsessive-compulsive disorder (OCD)? A case of successful augmentation with agomelatine for the treatment of OCD","volume":"34","author":"Correa","year":"2011","journal-title":"Clin. Neuropharmacol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.4088\/JCP.11m07493","article-title":"Agomelatine prevents relapse in generalized anxiety disorder: A 6-month randomized, double-blind, placebo-controlled discontinuation study","volume":"73","author":"Stein","year":"2012","journal-title":"J. Clin. Psychiatry"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"362","DOI":"10.4088\/JCP.13m08433","article-title":"Agomelatine in generalized anxiety disorder: An active comparator and placebo-controlled study","volume":"75","author":"Stein","year":"2014","journal-title":"J. Clin. Psychiatry"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1016\/j.pnpbp.2010.07.007","article-title":"Agomelatine in the treatment of social anxiety disorder","volume":"34","author":"Crippa","year":"2010","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"key":"ref_65","first-page":"241","article-title":"Agomelatine for the treatment of posttraumatic stress disorder: A case report","volume":"24","author":"Serroni","year":"2012","journal-title":"Ann. Clin. Psychiatry"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"9037","DOI":"10.3390\/ijms14059037","article-title":"Role of melatonin in schizophrenia","volume":"14","year":"2013","journal-title":"Int. J. Mol. Sci."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.pnpbp.2012.12.021","article-title":"Sleep and circadian rhythm dysregulation in schizophrenia","volume":"43","author":"Monti","year":"2013","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.schres.2010.03.031","article-title":"Discrepant nocturnal melatonin levels in monozygotic twins discordant for schizophrenia and its impact on sleep","volume":"120","author":"Afonso","year":"2010","journal-title":"Schizophr. Res."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1007\/s12031-011-9522-6","article-title":"Association of polymorphism in the promoter of the melatonin receptor 1A gene with schizophrenia and with insomnia symptoms in schizophrenia patients","volume":"45","author":"Park","year":"2011","journal-title":"J. Mol. Neurosci."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1097\/JCP.0b013e3181fbbb7d","article-title":"Diazepam discontinuation through agomelatine in schizophrenia with insomnia and depression","volume":"30","year":"2010","journal-title":"J. Clin. Psychopharmacol."},{"key":"ref_71","first-page":"347","article-title":"Nerve growth factor and brain-derived neurotrophic factor concentrations in schizophrenia: A review","volume":"26","author":"Martinotti","year":"2012","journal-title":"J. Biol. Regul. Homeost. Agents"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1097\/JCP.0000000000000157","article-title":"Augmentation of clozapine with agomelatine in partial-responder schizophrenia: A 16-week, open-label, uncontrolled pilot study","volume":"34","author":"Bruno","year":"2014","journal-title":"J. Clin. Psychopharmacol."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1111\/pcn.12032","article-title":"Agomelatine reversal of escitalopram-induced apathy: A case report","volume":"67","author":"Valchera","year":"2013","journal-title":"Psychiatry Clin. Neurosci."},{"key":"ref_74","first-page":"416","article-title":"Treatment of severe sleep disorder related to alcohol-dependence with high-dose agomelatine\u2014A case report","volume":"25","author":"Grosshans","year":"2013","journal-title":"Psychiatr. Danub."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/S1087-0792(03)90005-0","article-title":"Insomnia, alcoholism and relapse","volume":"7","author":"Brower","year":"2003","journal-title":"Sleep Med. Rev."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1097\/WNF.0000000000000007","article-title":"Agomelatine is effective in reducing insomnia in abstinent alcohol-dependent patients","volume":"37","author":"Grosshans","year":"2014","journal-title":"Clin. Neuropharmacol."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.berh.2011.01.002","article-title":"Myofascial pain syndromes and their evaluation","volume":"25","author":"Giamberardino","year":"2011","journal-title":"Best Pract. Res. Clin. Rheumatol."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"5291","DOI":"10.2741\/3598","article-title":"Neurobiology of depression, fibromyalgia and neuropathic pain","volume":"14","author":"Maletic","year":"2009","journal-title":"Front. Biosci."},{"key":"ref_79","unstructured":"Pernambuco, A.P., Schetino, L.P., Viana, R.S., Carvalho, L.S., and D\u02bc\u00c1vila Reis, D. (2014). The involvement of melatonin in the clinical status of patients with fibromyalgia syndrome. Clin. Exp. Rheumatol., in press."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1007\/s00296-011-2315-y","article-title":"Melatonin levels in premenopausal women with fibromyalgia syndrome","volume":"33","author":"Senel","year":"2013","journal-title":"Rheumatol. Int."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"167","DOI":"10.2174\/157015912800604489","article-title":"Melatonin in antinociception: Its therapeutic applications","volume":"10","author":"Srinivasan","year":"2012","journal-title":"Curr. Neuropharmacol."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1111\/j.1600-079X.2010.00836.x","article-title":"Adjuvant use of melatonin for treatment of fibromyalgia","volume":"50","author":"Hussain","year":"2011","journal-title":"J. Pineal Res."},{"key":"ref_83","first-page":"328","article-title":"Agomelatine adjunctive therapy for fibromyalgia","volume":"9","author":"Rico","year":"2013","journal-title":"Reumatol. Clin."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1055\/s-0033-1363659","article-title":"Agomelatine for the treatment of patients with fibromyalgia and depressive symptomatology: An uncontrolled, 12-week, pilot study","volume":"47","author":"Calandre","year":"2014","journal-title":"Pharmacopsychiatry"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1097\/JCP.0b013e31829057ae","article-title":"Agomelatine in the treatment of fibromyalgia: A 12-week, open-label, uncontrolled preliminary study","volume":"33","author":"Bruno","year":"2013","journal-title":"J. Clin. Psychopharmacol."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1016\/j.drudis.2014.04.014","article-title":"Melatonin: Functions and ligands","volume":"19","author":"Singh","year":"2014","journal-title":"Drug Discov. Today"},{"key":"ref_87","first-page":"104","article-title":"Chronobiology of migraine","volume":"110","author":"Tabeeva","year":"2010","journal-title":"Zh. Nevrol. Psikhiatr. Im. S. S. Korsakova"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1177\/0333102412455709","article-title":"Chronic headaches and insomnia: Working toward a biobehavioral model","volume":"32","author":"Ong","year":"2012","journal-title":"Cephalalgia"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1111\/j.1600-079X.2011.00895.x","article-title":"Analgesic effects of melatonin: A review of current evidence from experimental and clinical studies","volume":"51","author":"Wilhelmsen","year":"2011","journal-title":"J. Pineal Res."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1212\/01.WNL.0000134653.35587.24","article-title":"Melatonin, 3 mg, is effective for migraine prevention","volume":"63","author":"Peres","year":"2004","journal-title":"Neurology"},{"key":"ref_91","doi-asserted-by":"crossref","unstructured":"Fallah, R., Shoroki, F.F., and Ferdosian, F. (2014). Safety and efficacy of melatonin in pediatric migraine prophylaxis. Curr. Drug Saf.","DOI":"10.2174\/1574886309666140605114614"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1212\/WNL.0b013e3181f9618c","article-title":"Prophylaxis of migraine with melatonin: A randomized controlled trial","volume":"75","author":"Alstadhaug","year":"2010","journal-title":"Neurology"},{"key":"ref_93","first-page":"32","article-title":"Possibilities of preventive treatment of migraine with the MT1- and MT2 agonist and 5-HT2\u0441 receptor antagonist agomelatin (valdoxan)","volume":"111","author":"Tabeeva","year":"2011","journal-title":"Zh. Nevrol. Psikhiatr. Im. S. S. Korsakova"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1097\/WNF.0b013e3182800271","article-title":"A possible new option for migraine management: Agomelatine","volume":"36","author":"Guglielmo","year":"2013","journal-title":"Clin. Neuropharmacol."},{"key":"ref_95","doi-asserted-by":"crossref","unstructured":"Gahr, M., Kratzer, W., Fuchs, M., and Connemann, B.J. (2014). Safety and Tolerability of Agomelatine: Focus on Hepatotoxicity. Curr. Drug Metabol.","DOI":"10.2174\/1389200215666140926155041"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.4088\/JCP.08m04548","article-title":"Agomelatine prevents relapse in patients with major depressive disorder without evidence of a discontinuation syndrome: A 24-week randomized, double-blind, placebo controlled trial","volume":"70","author":"Goodwin","year":"2009","journal-title":"J. Clin. Psychiatry"},{"key":"ref_97","unstructured":"Servier Laboratories Ltd. Agomelatine (Valdoxan): Monitor liver function and do not use in people with high transaminase levels (>3X ULN) or \u2265 75 years, Available online:http:\/\/www.mhra.gov.uk\/home\/groups\/pl-p\/documents\/drugsafetymessage\/con333634.pdf."},{"key":"ref_98","unstructured":"Available online:http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/000915\/WC500046227.pdf."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1017\/S1092852914000248","article-title":"Mechanism of action of agomelatine: A novel antidepressant exploiting synergy between monoaminergic and melatonergic properties","volume":"19","author":"Stahl","year":"2014","journal-title":"CNS Spectr."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"3604","DOI":"10.1111\/bph.12720","article-title":"Agomelatine: Mechanism of action and pharmacological profile in relation to antidepressant properties","volume":"171","author":"Delagrange","year":"2014","journal-title":"Br. J. Pharmacol."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/16\/1\/1111\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T20:41:15Z","timestamp":1760215275000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/16\/1\/1111"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,1,5]]},"references-count":100,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2015,1]]}},"alternative-id":["ijms16011111"],"URL":"https:\/\/doi.org\/10.3390\/ijms16011111","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,1,5]]}}}